An expert discusses the evolving role of bispecific antibodies in multiple myeloma, highlighting their off-the-shelf availability, immune-targeting mechanism, and growing potential in relapsed and ...

An expert discusses the operational and financial complexities of integrating bispecific antibodies into multiple myeloma treatment pathways, emphasizing the need for standardized protocols, ...

An expert discusses the approval of a third bispecific antibody for relapsed/refractory multiple myeloma (R/R MM), highlighting its potential to reshape treatment pathways, intensify payer scrutiny ...